Back to Results
First PageMeta Content
Medicine / Integrase inhibitors / Amides / Organofluorides / Merck & Co. / Readington / New Jersey / Antiretroviral drug / HIV / Raltegravir / Chemistry / HIV/AIDS / Health


News Release _________________________________________________________________________ FOR IMMEDIATE RELEASE Media Contacts: Janet Skidmore
Add to Reading List

Document Date: 2006-09-17 23:24:53

Open Document

File Size: 26,36 KB

Share Result on Facebook

City

TORONTO / /

Company

Merck & Co. Inc. / Merck Research Laboratories / Since Merck / /

Country

United States / /

Event

FDA Phase / /

Facility

Whitehouse Station / /

IndustryTerm

treatment of HIV / pharmaceutical / /

MedicalCondition

HIV infection / greater disease / HIV / disease / acute hepatitis / Infectious Diseases / HIV/AIDS / clinically significant chronic liver disease / infection / /

MedicalTreatment

antiretroviral therapy / alternative therapy / investigational treatment / /

Organization

United Nations / /

Person

Graeme Bell / Randi Leavitt / Peter S. Kim / Janet Skidmore / /

/

Position

investigator / president / lead coordinator / Private / senior director / Infectious Diseases – Clinical Research / /

Product

HIV / HIV-1 / HIV/AIDS / MK-0518 / /

ProvinceOrState

New Jersey / /

URL

www.merck.com / /

SocialTag